PharmaCyte Biotech Reports Q3 2025 Financials: Revenue Stalls Amid Growing Losses and Decreased Cash Reserves

PharmaCyte Biotech, Inc. (OTCBB: PMCB) has recently published its quarterly report for the period ended January 31, 2025, highlighting key financial insights and operational updates.

Key Points:

• Revenue: $0 for both the three and nine months ended January 31, 2025 and 2024.
• Total operating expenses for Q3 2025 decreased to $960,252, down from $1,868,946 in Q3 2024.
• Net loss for Q3 2025 was $(3,045,328), compared to $(619,537) in Q3 2024.
• Net income for nine months ended January 31, 2025 was $18,906,468 compared to a loss of $(1,012,938) in the prior year.
• Cash and cash equivalents decreased to $16,383,460 from $50,179,968 as of April 30, 2024.
• Marketable equity securities valued at $372,632 as of January 31, 2025.
• Current liabilities decreased significantly to $1,194,384 from $7,421,264 as of April 30, 2024.
• Treasury stock increased to $44,434,656 from $42,040,216.

Positive Aspects:

• Reduction in total operating expenses suggests improved cost management, reflecting a decrease across R&D and administrative expenses.
• The company achieved a substantial net income increase over nine months due to gains from the revaluation of investments, highlighting operational resilience.
• The reduction in liabilities strengthens the balance sheet, potentially enhancing the company's negotiation position for future financing.

Negative Aspects:

• Continued lack of revenue generation remains a critical concern as the company has yet to commercialize its products.
• Net loss for Q3 highlights ongoing struggles with cost absorption despite significant revenue declines.
• Liquidity concerns are evident as cash reserves have principally depleted due to stock redemptions and significant R&D expenditures, raising questions about the company’s ability to fund operations without additional capital.

PharmaCyte continues to focus on obtaining FDA clearance for its IND application, a critical factor for future growth. However, protracted clinical hold and dependency on SG Austria’s IP could pose risks to timelines and operational focus.

For more detailed information, visit the [Company Page](https://stockinvest.us/stock/PMCB).